{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:20:25Z","timestamp":1778401225571,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jid.2017.07.835","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T06:00:14Z","timestamp":1503554414000},"page":"2491-2496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Influence of Market Competition on Tetracycline Pricing and Impact of Price Increases on Clinician Prescribing Behavior"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-4102","authenticated-orcid":false,"given":"John S.","family":"Barbieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A.","family":"Brod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2017.07.835_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jaad.2016.03.053","article-title":"The state and consequences of dermatology drug prices in the United States","volume":"75","author":"Albrecht","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2017.07.835_bib2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jaad.2017.01.032","article-title":"Future considerations for clinical dermatology in the setting of 21st century American policy reform: The Medicare Access and Children\u2019s Health Insurance Program Reauthorization Act and the Merit-based Incentive Payment System","volume":"76","author":"Barbieri","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2017.07.835_bib3","unstructured":"Bloomberg. U.S. charges in generic-drug probe to be filed by year-end, https:\/\/www.bloomberg.com\/news\/articles\/2016-11-03\/u-s-charges-in-generic-drug-probe-said-to-be-filed-by-year-end; 2016 (cited 2 May 2017)."},{"key":"10.1016\/j.jid.2017.07.835_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/0272989X14547740","article-title":"Cognitive biases and heuristics in medical decision making: a critical review using a systematic search strategy","volume":"35","author":"Blumenthal-Barby","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jid.2017.07.835_bib5","unstructured":"Centers for Medicare and Medicaid Services. NHE-Fact-Sheet, https:\/\/www.cms.gov\/research-statistics-data-and-systems\/statistics-trends-and-reports\/nationalhealthexpenddata\/nhe-fact-sheet.html; 2016 (cited 6 December 2016)."},{"key":"10.1016\/j.jid.2017.07.835_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/M16-1432","article-title":"High generic drug prices and market competition: a retrospective cohort study","volume":"167","author":"Dave","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jid.2017.07.835_bib7","unstructured":"Department of Justice. Herfindahl-Hirschman Index, https:\/\/www.justice.gov\/atr\/herfindahl-hirschman-index; 2015 (cited 7 May 2017)."},{"key":"10.1016\/j.jid.2017.07.835_bib8","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/acr.22880","article-title":"Specialty tier-level cost sharing and biologic agent use in the medicare part D initial coverage period among beneficiaries with rheumatoid arthritis","volume":"68","author":"Doshi","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jid.2017.07.835_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","article-title":"Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population","volume":"74","author":"Doshi","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2017.07.835_bib10","unstructured":"Food and Drug Administration. National Drug Code Directory, https:\/\/www.fda.gov\/drugs\/informationondrugs\/ucm142438.htm (cited 8 July 2017)."},{"key":"10.1016\/j.jid.2017.07.835_bib11","first-page":"CD002086","article-title":"Minocycline for acne vulgaris: efficacy and safety","volume":"8","author":"Garner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jid.2017.07.835_bib12","first-page":"1","article-title":"Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism?","volume":"775","author":"Gencarelli","year":"2002","journal-title":"NHPF Issue Brief"},{"key":"10.1016\/j.jid.2017.07.835_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJMp1704907","article-title":"Targeting unconscionable prescription-drug prices\u2014Maryland\u2019s anti-price-gouging law","volume":"377","author":"Greene","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2017.07.835_bib14","unstructured":"Humer C. Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival. Reuters, http:\/\/www.reuters.com\/article\/us-express-scripts-abbvie-hepatitisc-idUSKBN0K007620141222; 2014 (cited 2 July 2017)."},{"key":"10.1016\/j.jid.2017.07.835_bib15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamadermatol.2017.1129","article-title":"Generic drugs\u2014changes in cost and challenges in practice","volume":"153","author":"Kirby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2017.07.835_bib16","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1365-2133.2012.10845.x","article-title":"Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature","volume":"166","author":"Lebrun-Vignes","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2017.07.835_bib17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000238249","article-title":"Bioavailability of doxycycline monohydrate. A comparison with equivalent doses of doxycycline hydrochloride","volume":"30","author":"Malmborg","year":"1984","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jid.2017.07.835_bib18","doi-asserted-by":"crossref","first-page":"h4112","DOI":"10.1136\/bmj.h4112","article-title":"Medicare could save up to $16bn if allowed to negotiate drug prices, paper finds","volume":"351","author":"McCarthy","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2017.07.835_bib19","unstructured":"McElhaney A. Twenty more states accuse Mylan, Teva and others of price collusion. TheStreet, https:\/\/www.thestreet.com\/story\/14022831\/1\/twenty-more-states-accuse-mylan-teva-and-others-of-price-collusion.html; 2017 (cited 2 May 2017)."},{"key":"10.1016\/j.jid.2017.07.835_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1046\/j.1365-3156.2002.00941.x","article-title":"Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis","volume":"7","author":"Pag\u00e8s","year":"2002","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jid.2017.07.835_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jamadermatol.2015.3897","article-title":"Changes in retail prices of prescription dermatologic drugs from 2009 to 2015","volume":"152","author":"Rosenberg","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2017.07.835_bib22","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jamadermatol.2015.2394","article-title":"Variation in the cost of generic topical corticosteroids","volume":"151","author":"Skojec","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2017.07.835_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: a systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.jid.2017.07.835_bib24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamadermatol.2017.1130","article-title":"Medicare Part D payments for topical steroids: rising costs and potential savings","volume":"153","author":"Song","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2017.07.835_bib25","series-title":"Generic drugs under Medicare: Part D generic drug prices declined overall, but some had extraordinary price increases","year":"2016"},{"key":"10.1016\/j.jid.2017.07.835_bib26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2017.07.835_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17327963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17327963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T17:59:42Z","timestamp":1555351182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X17327963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0022202X17327963"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2017.07.835","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Market Competition on Tetracycline Pricing and Impact of Price Increases on Clinician Prescribing Behavior","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2017.07.835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}